It is very uncertain whether steroids changes adverse effect: incident elevated IOP ( compared with cyclosporine A (very low certainty).
The review found no eligible studies for this question.
Steroids showed no clear difference in change in patient‐reported symptom scores (lower is favored) compared with cyclosporine A (low certainty).
The review found no eligible studies for this question.
Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).
Mycophenolate mofetil may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).
Mycophenolate mofetil may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: reduced GFR compared with cyclosporin (low certainty).
Alkylating agents showed no clear difference in relapse at end of therapy (6 to 9 months) compared with cyclosporin (low certainty).
Alkylating agents may leads to lower relapse at 12 to 24 months compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Alkylating agents showed no clear difference in adverse effects: serum creatinine compared with cyclosporin (low certainty).
Alkylating agents may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
Alkylating agents may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).
It is very uncertain whether alkylating agents changes adverse effects: hypertension compared with cyclosporin (very low certainty).